Kanker paru merupakan salah satu penyebab utama kematian karena kanker di seluruh dunia melebihi angka kematian karena kanker payudara, prostat, dan usus besar. Angka kejadian kasus baru kanker paru di Amerika Serikat diperkirakan sekitar dua ratus tiga puluh sembilan ribu (239.320) orang dengan angka kematiannya sekitar seratus enam puluh satu ribu (161.250) orang pada tahun 2010. Sekitar 85% kasus kanker paru adalah jenis KPKBSK yang penyebarannya ke bagian tubuh lainnya lebih lambat dengan angka kesintasan selama 5 tahun lebih tinggi daripada kanker paru jenis lainnya yakni KPKSK. Radioterapi merupakan salah satu modalitas untuk terapi kanker paru (khususnya jenis KPKBSK) yang pada umumnya diberikan dalam bentuk EBRT baik dalam bentuk terapi tunggal atau sebagai bagian dari modalitas terapi lainnya, dan dapat bersifat kuratif atau paliatif. Sementara itu pemberian EBRT pada kanker paru jenis KPKSK juga dapat dilakukan untuk tujuan profilaksis terhadap terjadinya metastasis ke otak. Pemberian EBRT pada kanker paru tentunya harus melalui beberapa tahapan prosedur pemberiannya untuk menghasilkan efek radioterapi pada kanker paru yang maksimal
Background: Lung cancer and pulmonary tuberculosis (TB) are global health problem. Similarity of symptoms of both made misdiagnose of lung cancer as TB and treated with Anti Tuberculosis Treatment (ATT). Evaluation of ATT often inaccurate, causing late diagnosis of lung cancer. This study aimed is to determine the lung cancer percentage with delayed diagnosis due giving of ATT for >1 month.
Methods: A prospective descriptive study was performed from January 2014-February 2016 in Dr. Moewardi Hospital, Surakarta taken from the patient's medical record.
Results: As much 293 patients with lung cancer consisted of 188 males (64.4%) and 105 females (35.8%) with the average age was 57 years old. The types of the lung cancer were non-small cell lung carcinoma (NSCLC) consisted of adenocarcinoma 195 subjects (66.6%), squamous cell carcinoma 65 subjects (22.2%), large cell carcinoma 23 subjects (7.8%) and neuroendocrine carcinoma 4 subjects (1.4%). The stages of the NSCLC were stage I (0%), II (0%), IIIa (0%), IIIb (11.7%) and IV (88.3%). Among 293 lung cancer patients, 89 subjects (30.4%) were diagnosis as pulmonary TB. Two subjects (2.2%) of 89 subjects were truly pulmonary TB while the rest 87 subjects were not pulmonary TB and had ATT for average 12 weeks with the longest period was 16 weeks. The ATT duration >1 month was 76.4%.
Conclusions: Percentage of lung cancer patients with ATT before being referred to dr. Moewardi hospital were 30.4% of 293 lung cancer patients while 68 subjects (76.4%) of whom had received ATT >1 month. (J Respir Indo. 2017; 37(4): 288-92)
Introduction: A granular cell tumor is a rare neoplasm originating from mesenchymal tissue. Malignant granular cell tumors have a poor prognosis. The lung is one of the target organs for metastatic malignant granular cell tumors. The number of rare cases makes managing metastatic malignant granular cell tumors unknown.
Case: A 19-year-old male complained of shortness of breath for two months. A liver nodule biopsy revealed poorly differentiated carcinoma metastases. Histopathology of the left manus and frontal masses found granular cell tumors—negative immunohistochemistry on S-100 and myogenin. Ki-67 obtained a value of 5%. An X-ray and contrast multislice computerized tomography (MSCT) scan showed multiple metastatic nodules. Right bronchial biopsy forceps revealed a metastatic granular cell tumor. The patient was given docetaxel for six cycles. During the post-administration of docetaxel, the patient experienced clinical and radiological improvement.
Conclusion: Until 2016, only three case reports of S-100 negative granular cell tumors existed. A negative S-100 test does not rule out the diagnosis of granular cell tumors. Malignant lesions are more common in males, as in this case. The number of rare cases means that management cannot be determined. Reports of similar cases show patients surviving up to 11 years with docetaxel administration. The patient in this study has survived for one year and is complaint-free.
Background: Most adenocarcinoma lung cancer which is found at an advanced stage with cytology / histopathological samples is hardly available. Examination of EGFR mutations in ctDNA blood plasma sampling is simpler and easier, which also can be used as predictive and prognostic markers in non-small cell carcinoma lung cancer patients. The purpose of this study is to determine and analyse the degree of compatibility between examination of EGFR mutations by blood plasma (ctDNA) samples with the examination of cytology / histopathological EGFR mutations in adenocarcinoma lung cancer.
Methods: Diagnostic test research, by taking medical records of patients with adenocarcinoma lung cancer from January to September 2019 at Dr. Moewardi Surakarta, who was examined by EGFR mutations in cytology / histopathology and ctDNA samples.
Result: The Subjects of this study were 73 patients with adenocarcinoma lung cancer. The level of compatibility of ctDNA with EGFR mutations in cytology / histopathology samples was categorized as moderate and statistically significant (Kappa = 0.459; p = 0.000).
Conclusion: The level of concordance between the examination of EGFR mutations with blood plasma samples (ctDNA) with the examination of EGFR mutations in cytology / histopathology samples was moderate and statistically significant.
Backgrounds: Pulmonary rehabilitation is a non-pharmacological therapy that improves breathing capacity in lung cancer patients. This study aimed to determine the effects of incentive spirometry (IS) on exercise capacity, breathing symptoms, depression rates, and quality of life in lung cancer patients with chemotherapy.
Method: This quasi-experimental study was done through purposive sampling of 32 lung cancer patients who underwent chemotherapy for at least three cycles at Dr. Moewardi General Regional Hospital, Surakarta, from December 2019 to February 2020.Data on 6 minutes walking test (6-MWT) to evaluate exercise capacity, breathing symptoms (BORG scale), level of depression (HRSD questionnaire), and quality of life (SGRQ questionnaire) .
Results: Experimental group showed higher value of 6-MWT (72.75±152.50 meters vs. 31.81 ± 27.67, P=0.010), a decrease in the BORG scale (-1.78±1.72 vs. -0.38±1.67, P=0.013), Hamilton's score improvement (-2.25±5.12 vs. -4.25±5.34, P=0.075), and improvement in the SGRQ value (-10.77±9.82 vs. -0.08±11.16, P=0.752) compared to those of control group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.